UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

British journal of cancer, 2008-12, Vol.99 (12), p.2006-2012

2008

Volltextzugriff (PDF)

Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss

Cancer chemotherapy and pharmacology, 2005-10, Vol.56 (4), p.391-399

2005

Volltextzugriff (PDF)

Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel

Neurotoxicology (Park Forest South), 2007-11, Vol.28 (6), p.1092-1098

2007

Volltextzugriff (PDF)

Lobaplatin: a new antitumour platinum drug

Expert opinion on investigational drugs, 2001-01, Vol.10 (1), p.119-128

McKeage, Mark J

2001

Volltextzugriff (PDF)

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

British journal of cancer, 2000-02, Vol.82 (4), p.966-972

2000

Volltextzugriff (PDF)

Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)

Annals of oncology, 2018-10, Vol.29, p.viii745-viii745

2018

Volltextzugriff (PDF)

Nucleolar damage correlates with neurotoxicity induced by different platinum drugs

British journal of cancer, 2001-10, Vol.85 (8), p.1219-1225

2001

Volltextzugriff (PDF)

Comparative adverse effect profiles of platinum drugs

Drug safety, 1995-10, Vol.13 (4), p.228-244

MCKEAGE, M. J

1995

Volltextzugriff (PDF)

Primary efficacy and updated safety of ceritinib (450mg or 600mg) with food vs 750mg fasted in ALK+ metastatic NSCLC (ASCEND-8)

Annals of oncology, 2018-10, Vol.29, p.viii747-viii747

2018

Volltextzugriff (PDF)

Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1145-1154

2012

Volltextzugriff (PDF)

598 A Phase 1b Study of Demcizumab Plus Pemetrexed and Carboplatin in Patients with 1st Line Non-Small Cell Lung Cancer (NSCLC)

European journal of cancer (1990), 2012-11, Vol.48, p.183-184

2012

Volltextzugriff (PDF)

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-08, Vol.377 (9), p.829-838

2017

Volltextzugriff (PDF)

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

Journal of inorganic biochemistry, 1999-10, Vol.77 (1), p.105-110

1999

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

Journal of clinical oncology, 1997-07, Vol.15 (7), p.2691-2700

1997

Volltextzugriff (PDF)

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV) : an orally active platinum drug

Cancer research (Chicago, Ill.), 1993-06, Vol.53 (11), p.2581-2586

1993

Volltextzugriff (PDF)

Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity

British journal of cancer, 2003-06, Vol.88 (12), p.1942-1947

2003

Volltextzugriff (PDF)

Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes

Cancer chemotherapy and pharmacology, 2000, Vol.46 (5), p.343-350

2000

Volltextzugriff (PDF)

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

Journal of clinical oncology, 1998-05, Vol.16 (5), p.1948-1953

1998

Volltextzugriff (PDF)

P1.18-05 Te Oranga Pūkahukahu: Developing an Indigenous Māori Led Approach to Lung Cancer Screening

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S228

2023

Volltextzugriff (PDF)

P84.05 Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S657-S658

2021

Volltextzugriff (PDF)

Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.7102-7102

McKeage, M.

2006

Volltextzugriff (PDF)

5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent

Clinical cancer research, 2006-03, Vol.12 (6), p.1776-1784

2006

Volltextzugriff (PDF)

390O - Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

Annals of oncology, 2019-10, Vol.30, p.v143-v144

2019

Volltextzugriff (PDF)

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

Annals of oncology, 2019-10, Vol.30, p.v143-v144

2019

Volltextzugriff (PDF)

Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer

Journal of medicinal chemistry, 1997-03, Vol.40 (7), p.1090-1098

1997

Volltextzugriff (PDF)

1 – 25 von 173

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(157)

Publikationsform

Sprache

Englisch
(173)
Japanisch
(12)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(76)
Humans
(68)
Biological And Medical Sciences
(56)
Medical Sciences
(56)
Pharmacology. Drug Treatments
(49)
Pharmacology & Pharmacy
(39)
Female
(38)
Animals
(35)
Oncology
(33)
Antineoplastic Agents
(27)
Adult
(20)
Chemotherapy
(20)
Male
(20)
Medicine
(17)
Middle Aged
(17)
Pharmacotherapy
(17)
Toxicology
(17)
Medicine & Public Health
(16)
Antineoplastic Agents - Pharmacokinetics
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss

Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel

Lobaplatin: a new antitumour platinum drug

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)

Nucleolar damage correlates with neurotoxicity induced by different platinum drugs

Comparative adverse effect profiles of platinum drugs

Primary efficacy and updated safety of ceritinib (450mg or 600mg) with food vs 750mg fasted in ALK+ metastatic NSCLC (ASCEND-8)

Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial

598 A Phase 1b Study of Demcizumab Plus Pemetrexed and Carboplatin in Patients with 1st Line Non-Small Cell Lung Cancer (NSCLC)

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV) : an orally active platinum drug

Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity

Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

P1.18-05 Te Oranga Pūkahukahu: Developing an Indigenous Māori Led Approach to Lung Cancer Screening

P84.05 Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial

Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC)

5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent

390O - Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer

Suchergebnisse filtern